Targets › CSF2
3 programs from 3 companies in 4 trials: 2 Phase 3, 2 Phase 2; Oncology, Hematology, Immunology; next expected readout Dec 2026.
Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. (UniProt, P04141)
Open in Phaseline: the race on CSF2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TJ Biopharma | Plonmarlimab Granulocyte-macrophage colony-stimulating factor antagonist | CSF2 | Phase 3 | Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis; Acute Gouty Arthritis | Dec 2026 |
| BriaCell Therapeutics | SV-BR-1-GM Allogeneic whole cell breast tumor cell line transfected with CSF2 gene encoding GM-CSF; p | CSF2 | Phase 3 | Breast Cancer | Dec 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | GVAX Pancreas Vaccine GM-CSF-transfected allogeneic pancreatic tumor cell vaccine | CSF2 | Phase 2 | Pancreatic Cancer | – |
Breast Cancer (1) Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (1) Acute Gouty Arthritis (1) Pancreatic Cancer (1)
mixed (3)
BriaCell Therapeutics (1) TJ Biopharma (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.